We are live on ! Find out more
DMAC icon

DiaMedica Therapeutics
DMAC

28 hedge funds and large institutions have $7.42M invested in DiaMedica Therapeutics in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

207% more call options, than puts

Call options by funds: $175K | Put options by funds: $57K

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

1.27% less ownership

Funds ownership: 15.16% → 13.88% (-1.3%)

18% less funds holding

Funds holding: 34 → 28 (-6)

26% less capital invested

Capital invested by funds: $10M → $7.42M (-$2.6M)

86% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 7

Holders
28
Holders Change
-6
Holders Change %
-17.65%
% of All Funds
0.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
7
Reduced
6
Closed
7
Calls
$175K
Puts
$57K
Net Calls
+$118K
Net Calls Change
+$48K

Top Buyers

Rank Fund Capital Flow
1
CF
Cantor Fitzgerald
New York
+$34.3K
2
Morgan Stanley
Morgan Stanley
New York
+$33.5K
3
BlackRock
BlackRock
New York
+$24K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$5.05K
5
UBS Group
UBS Group
Switzerland
+$4.85K

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$553K
2
Two Sigma Investments
Two Sigma Investments
New York
-$76.6K
3
JAMONY
Jacob Asset Management of New York
California
-$61.8K
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$53K
5
BFM
Boothbay Fund Management
New York
-$52K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Stonepine Capital Management
Oregon
$2.38M -$48.8K -20,901 -2%
CLG
2
Cooperman Leon G
$1.64M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$1.58M – – –
JAMONY
4
Jacob Asset Management of New York
California
$482K -$61.8K -26,500 -10%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$357K +$5.05K +2,164 +1%
Northern Trust
6
Northern Trust
Illinois
$206K +$4.11K +1,762 +2%
State Street
7
State Street
Massachusetts
$135K – – –
BlackRock
8
BlackRock
New York
$135K +$24K +10,278 +18%
Dimensional Fund Advisors
9
Dimensional Fund Advisors
Texas
$117K – – –
Morgan Stanley
10
Morgan Stanley
New York
$96K +$33.5K +14,377 +43%
Bank of New York Mellon
11
Bank of New York Mellon
New York
$73K -$383 -164 -0.5%
Two Sigma Advisers
12
Two Sigma Advisers
New York
$54K -$53K -22,700 -46%
Citadel Advisors
13
Citadel Advisors
Florida
$36K -$47.2K -20,220 -53%
Two Sigma Investments
14
Two Sigma Investments
New York
$35K -$76.6K -32,819 -66%
CF
15
Cantor Fitzgerald
New York
$30K +$34.3K +14,691 New
SC
16
Shay Capital
New York
$20K – – –
MPWT
17
MassMutual Private Wealth & Trust
Connecticut
$10K – – –
US Bancorp
18
US Bancorp
Minnesota
$9K – – –
TRCT
19
Tower Research Capital (TRC)
New York
$6K +$2.57K +1,102 +66%
UBS Group
20
UBS Group
Switzerland
$6K +$4.85K +2,080 +219%
TWC
21
TD Waterhouse Canada
Ontario, Canada
$3.89K – – –
NFSG
22
Newbridge Financial Services Group
Florida
$3K – – –
PFGIA
23
Patriot Financial Group Insurance Agency
Massachusetts
$2K – – –
Royal Bank of Canada
24
Royal Bank of Canada
Ontario, Canada
$2K – – –
FDCDDQ
25
Federation des caisses Desjardins du Quebec
Quebec, Canada
$465 – – –
1
2

DMAC Hedge Fund Activity: Q2 2022 in Review

28 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q2 2022, worth a combined $7.42M — down 26% from $10M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of DMAC and 1 opened new positions — a net loss of 6 holders — while 6 trimmed existing stakes and 7 added.

The largest buyer was Cantor Fitzgerald, opening a new position worth an estimated $34.3K. The largest seller was Ikarian Capital, exiting entirely with an estimated $553K sold.

  • 28 institutional investors held DiaMedica Therapeutics (DMAC) as of Q2 2022, down from 34 in Q1 2022.
  • Funds reported $7.42M of DiaMedica Therapeutics stock for Q2 2022, down 26% quarter-over-quarter.
  • 1 fund opened new DiaMedica Therapeutics positions in Q2 2022 and 7 closed out, a net change of -6 holders.
  • The largest DiaMedica Therapeutics buyer in Q2 2022 was Cantor Fitzgerald, an estimated $34.3K added.
  • The largest DiaMedica Therapeutics seller in Q2 2022 was Ikarian Capital, an estimated $553K sold.

Based on aggregated 13F filings for Q2 2022.